Ensysce Biosciences Q1 2024 GAAP EPS $(0.55) Beats $(0.90) Estimate, Sales $305.722K Miss $400.000K Estimate
Ensysce Biosciences Q1 2024 GAAP EPS $(0.55) Beats $(0.90) Estimate, Sales $305.722K Miss $400.000K Estimate
Ensysce Biosciences 2024年第一季度GAAP每股收益（0.55）超過預期（0.90），銷售額爲305.722萬美元，未達到400.000萬美元的預期
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.90) by 38.89 percent. The company reported quarterly sales of $305.722 thousand which missed the analyst consensus estimate of $400.000 thousand by 23.57 percent. This is a 61.28 percent decrease over sales of $789.635 thousand the same period last year.
Ensysce Biosciences（納斯達克股票代碼：ENSC）公佈的季度虧損爲每股0.55美元，比分析師普遍預期的0.90美元（0.90美元）高出38.89％。該公司公佈的季度銷售額爲305,722美元，比分析師普遍預期的40萬美元低23.57％。這比去年同期的789,635美元的銷售額下降了61.28％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。